Cargando…
Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480026/ https://www.ncbi.nlm.nih.gov/pubmed/26100024 http://dx.doi.org/10.1136/bmjopen-2014-006996 |
_version_ | 1782378109852450816 |
---|---|
author | Coop, Catherine Edlin, Richard Brown, Julie Farquhar, Cindy |
author_facet | Coop, Catherine Edlin, Richard Brown, Julie Farquhar, Cindy |
author_sort | Coop, Catherine |
collection | PubMed |
description | OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening (glycated haemoglobin (HbA1c) test at first booking and a 2 h 75 g oral glucose tolerance test (OGTT) as a single test at 24–28 weeks) with 3-step screening (HbA1c test at first booking and a 1 h glucose challenge test (GCT) followed by a 2 h 75 g OGTT when indicated from 24–28 weeks) using a 9-month time horizon. SETTING: A hypothetical cohort of 62 000 pregnant women in New Zealand. METHODS: Probabilities, costs and benefits were derived from the literature, and supplementary data was obtained from National Women's Annual Clinical Reports. Main outcome measures, screening and treatment costs (NZ$2013) and effect on health outcomes (incidence of complications). RESULTS: The total cost for both strategies under baseline assumptions shows that the 2-step screening strategy would cost NZ$1.38 m more than the 3-step screening strategy overall. The additional cost per case detected was NZ$12 460 per case. The model found that the 2-step screening strategy identifies 12 more women with diabetes and 111 more women with GDM when compared against the 3-step screening strategy. We assessed the effect of changing the sensitivity and specificity of the OGTT. The baseline model assumed that the 2 h 75 g OGTT has a sensitivity and specificity of 95%. The 2-step strategy becomes more cost-effective when the diagnostic accuracy measures are improved. CONCLUSIONS: Adopting a 2-step strategy would moderately increase the number of GDM cases detected at the same time as moderately increasing the number of women with false negatives at a significant cost to the health system. Further evidence on the benefits of the 2 different approaches would be welcome. |
format | Online Article Text |
id | pubmed-4480026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44800262015-07-02 Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations Coop, Catherine Edlin, Richard Brown, Julie Farquhar, Cindy BMJ Open Obstetrics and Gynaecology OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening (glycated haemoglobin (HbA1c) test at first booking and a 2 h 75 g oral glucose tolerance test (OGTT) as a single test at 24–28 weeks) with 3-step screening (HbA1c test at first booking and a 1 h glucose challenge test (GCT) followed by a 2 h 75 g OGTT when indicated from 24–28 weeks) using a 9-month time horizon. SETTING: A hypothetical cohort of 62 000 pregnant women in New Zealand. METHODS: Probabilities, costs and benefits were derived from the literature, and supplementary data was obtained from National Women's Annual Clinical Reports. Main outcome measures, screening and treatment costs (NZ$2013) and effect on health outcomes (incidence of complications). RESULTS: The total cost for both strategies under baseline assumptions shows that the 2-step screening strategy would cost NZ$1.38 m more than the 3-step screening strategy overall. The additional cost per case detected was NZ$12 460 per case. The model found that the 2-step screening strategy identifies 12 more women with diabetes and 111 more women with GDM when compared against the 3-step screening strategy. We assessed the effect of changing the sensitivity and specificity of the OGTT. The baseline model assumed that the 2 h 75 g OGTT has a sensitivity and specificity of 95%. The 2-step strategy becomes more cost-effective when the diagnostic accuracy measures are improved. CONCLUSIONS: Adopting a 2-step strategy would moderately increase the number of GDM cases detected at the same time as moderately increasing the number of women with false negatives at a significant cost to the health system. Further evidence on the benefits of the 2 different approaches would be welcome. BMJ Publishing Group 2015-06-22 /pmc/articles/PMC4480026/ /pubmed/26100024 http://dx.doi.org/10.1136/bmjopen-2014-006996 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Obstetrics and Gynaecology Coop, Catherine Edlin, Richard Brown, Julie Farquhar, Cindy Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title | Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title_full | Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title_fullStr | Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title_full_unstemmed | Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title_short | Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations |
title_sort | cost-effectiveness of the new zealand diabetes in pregnancy guideline screening recommendations |
topic | Obstetrics and Gynaecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480026/ https://www.ncbi.nlm.nih.gov/pubmed/26100024 http://dx.doi.org/10.1136/bmjopen-2014-006996 |
work_keys_str_mv | AT coopcatherine costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations AT edlinrichard costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations AT brownjulie costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations AT farquharcindy costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations |